PMID- 30350884
OWN - NLM
STAT- MEDLINE
DCOM- 20200123
LR  - 20200123
IS  - 1520-6777 (Electronic)
IS  - 0733-2467 (Linking)
VI  - 38
IP  - 1
DP  - 2019 Jan
TI  - Meta-analysis of the efficacy and safety of mirabegron and solifenacin 
      monotherapy for overactive bladder.
PG  - 22-30
LID - 10.1002/nau.23863 [doi]
AB  - AIM: We conducted a meta-analysis to evaluate the safety and efficacy of 
      mirabegron (50 mg) and solifenacin (5 mg) monotherapy for overactive bladder 
      (OAB) during a 12-week cycle. METHODS: Randomized controlled trials (RCTs) of 
      mirabegron and solifenacin for OAB were searched systematically by using MEDLINE, 
      EMBASE, and the Cochrane Controlled Trials Register. The reference lists of 
      retrieved studies were also perused. RESULTS: Five RCTs which compared 
      solifenacin with mirabegron were studied. Mirabegron achieved the same effect as 
      solifenacin in treating OAB. The mean number of incontinence episodes per 24 h 
      (P = 0.20), mean number of micturitions per 24 h (P = 0.11), mean number of 
      urgency episodes per 24 h (P = 0.23), and mean volume voided per micturition 
      (P = 0.05) suggested that mirabegron and solifenacin had no significant 
      differences in terms of OAB treatment. With regard to drug-related 
      treatment-emergent adverse events (DR-TEAEs) and dry mouth, mirabegron showed 
      better tolerance than solifenacin. Post-voiding residual volume showed a distinct 
      difference in the two groups. Hypertension and tachycardia did not show a 
      significant difference between the two groups, but the pulse rate did. 
      CONCLUSION: The therapeutic effect of mirabegron is similar to that of 
      solifenacin, and mirabegron does not increase the risk of adverse events (AEs).
CI  - (c) 2018 Wiley Periodicals, Inc.
FAU - Wang, Jipeng
AU  - Wang J
AUID- ORCID: 0000-0002-3240-7863
AD  - Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao 
      University, Yantai, Shandong, China.
FAU - Zhou, Zhongbao
AU  - Zhou Z
AUID- ORCID: 0000-0002-9810-8145
AD  - Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao 
      University, Yantai, Shandong, China.
FAU - Cui, Yuanshan
AU  - Cui Y
AD  - Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao 
      University, Yantai, Shandong, China.
FAU - Li, Yongwei
AU  - Li Y
AD  - Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao 
      University, Yantai, Shandong, China.
FAU - Yuan, Hejia
AU  - Yuan H
AD  - Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao 
      University, Yantai, Shandong, China.
FAU - Gao, Zhenli
AU  - Gao Z
AD  - Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao 
      University, Yantai, Shandong, China.
FAU - Zhu, Zhe
AU  - Zhu Z
AD  - Department of Stem Cell Biology and Regenerative Medicine, Lerner Research 
      Institute, Cleveland Clinic, Cleveland, Ohio.
FAU - Wu, Jitao
AU  - Wu J
AD  - Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao 
      University, Yantai, Shandong, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20181023
PL  - United States
TA  - Neurourol Urodyn
JT  - Neurourology and urodynamics
JID - 8303326
RN  - 0 (Acetanilides)
RN  - 0 (Thiazoles)
RN  - 0 (Urological Agents)
RN  - KKA5DLD701 (Solifenacin Succinate)
RN  - MVR3JL3B2V (mirabegron)
SB  - IM
CIN - Neurourol Urodyn. 2019 Aug;38(6):1792. PMID: 31157924
MH  - Acetanilides/adverse effects/*therapeutic use
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - Solifenacin Succinate/adverse effects/*therapeutic use
MH  - Thiazoles/adverse effects/*therapeutic use
MH  - Urinary Bladder, Overactive/*drug therapy
MH  - Urological Agents/adverse effects/*therapeutic use
OTO - NOTNLM
OT  - meta-analysis
OT  - mirabegron
OT  - overactive bladder
OT  - randomized controlled trials
OT  - solifenacin
EDAT- 2018/10/24 06:00
MHDA- 2020/01/24 06:00
CRDT- 2018/10/24 06:00
PHST- 2018/05/19 00:00 [received]
PHST- 2018/09/12 00:00 [accepted]
PHST- 2018/10/24 06:00 [pubmed]
PHST- 2020/01/24 06:00 [medline]
PHST- 2018/10/24 06:00 [entrez]
AID - 10.1002/nau.23863 [doi]
PST - ppublish
SO  - Neurourol Urodyn. 2019 Jan;38(1):22-30. doi: 10.1002/nau.23863. Epub 2018 Oct 23.